z-logo
open-access-imgOpen Access
CLL: Phase III Studies Confirm Added Rituximab Better than Chemo Alone
Author(s) -
Peter Goodwin
Publication year - 2009
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000345893.78014.42
Subject(s) - rituximab , fludarabine , medicine , cyclophosphamide , regimen , neutropenia , toxicity , progression free survival , chronic lymphocytic leukemia , gastroenterology , clinical endpoint , chemotherapy , oncology , surgery , leukemia , clinical trial , lymphoma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom